Archives — March 2018 back to current month (10)
The company performed strongly in the U.S. and the Asia Pacific region.
A recent conference call provided clinical and financial updates.
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night.
Two Biotechs Earn Analyst's Top Pick Ranking (03/19/2018)
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well.
Price Target on Biotech Is a 700% Potential Increase (03/19/2018)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease.
H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset.
Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm.
John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment.
Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs.
Technical analyst Clive Maund takes a look at a biotech stock that he views as a strong buy.
|"PMN is looking to outlicense PMN310 after the Phase 1 study."|
|"VIVs recent distribution deals illustrate demand for its technology."|
|"DRRX intends to start a NASH trial as soon as H1/19."|